The Global Lateral Flow Assays Market size accounted for USD 8,256 Million in 2021 and is expected to reach USD 13,317 Million by 2030, growing at a CAGR of 5.5% during the forecast period from 2022 to 2030.
Lateral flow assays (LFAs) are convenient paper-based equipment that detects the presence or absence of an objective analyte in a fluid sample matrix. It has sparked interest due to its short analyte times, user-friendly formats, low external interference, cheap costs, and simplicity of handling by non-specialized personnel. LFA-based assessments are widely used in clinical, hospital, and diagnostic settings for the descriptive and analytical identification of antibodies and antigens, as well as genomic amplification product offerings. However, the high prevalence of communicable diseases worldwide, rising demand for point-of-care diagnostics, rapid population aging, and increased use of home-based rapid diagnostic equipment are the primary factors driving lateral flow assay market revenue.
Lateral Flow Assays Market Dynamics
|Market||Lateral Flow Assays Market|
|Market Size 2021||USD 8,256 Million|
|Market Forecast 2030||USD 13,317 Million|
|CAGR During 2022 - 2030||5.5%|
|Analysis Period||2018 - 2030|
|Forecast Data||2022 - 2030|
|Segments Covered||By Product, By Application, By Technique, By End-user, And By Geography
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche AG, Merck KGAA, Biomérieux SA, PerkinElmer, Inc., Hologic, Inc., Quidel Corporation, Becton, Dickinson and Company, Bio-rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and Danaher Corporation.|
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
10 hrs of free customization and expert consultation
The lateral flow assay is an early detection method based on the biological interaction of a monoclonal antibody with DNA. This procedure ensures that the test is carried out in a highly simplified, low-cost, and interference-free manner. It can also be performed by untrained individuals since it is based on a very consumer type of assessment.
As the prevalence of coronavirus disease has increased, so has the need for a potential substitute for collecting samples and transmitting data from patients to laboratories. The complete lack of comprehensive clinical laboratories or qualified health care workers to conveniently perform polymerase chain reaction (PCR) tests is one of the key factors driving the lateral flow assay market trend. LFA kits and reagents are more efficient, smaller, and more compact, with only minor training required. They are a one-step assay with no need for rinsing, cooling systems, or sample preparation. They also have faster testing procedures that provide subjective or moderately accurate results are relatively quick to develop and allow for batch preparation ahead of time. Aside from that, the incidence of highly contagious diseases is increasing, necessitating the development of new screening techniques for effective treatment. This, together with substantially increased awareness campaigns to reduce infection spread, diagnostic tests, and preventative measures will contribute to market growth.
Lateral Flow Assays Market Segmentation
The global lateral flow assays market segmentation is based on the product, application, technique, end-use and geography.
Market by Product
Based on the product, the kit segment will hold the majority of market shares in the forecasting years due to the large extended functionality for lateral flow testing kits to recognize any immunoglobulin such as the COVID-19 viral infection. Furthermore, the worldwide spread of numerous chronic and infectious diseases, as well as the substantial majority of lateral flow assay rapid diagnostic kits introduced by industry leaders, primarily for COVID-19 testing, are the primary factors driving the segment in the market over the coming years.
Market by Application
Based on the application, infection disease testing is expected to grow at the fastest rate in the coming years, owing to the rising prevalence of chronic diseases and the increased demand for patient-centered care. Furthermore, an increase in government initiatives to promote health awareness, an increase in public knowledge and understanding of preclinical development, and an increase in the global occurrence and prevalence of chronic diseases will drive the segment in the coming years. Furthermore, continuous advancements and innovations in lateral flow assays for leading chronic health conditions are expected to drive segment growth.
Market by Technique
Based on the technique, the sandwich assays segment accounted the largest lateral flow assay market share in 2021, owing to rising demand and increased awareness of the comprehensive benefits provided by the sandwich assay system in diagnostic tests such as drug abuse testing, pregnancy & fertility testing, and many more. In this technique, a positive test is mostly represented by a different colored line at the test line position. The sandwich assays test is also applicable in any low-resource care coordination or specialist setting, and no, proper training is not required. The expanding range of research operations carried out by various research organizations is expected to drive the market
Market by End-use
In terms of end-use, the hospital and clinics segment is anticipated to lead the global market in 2021. Advancements in technology, increased use of point-of-care testing, and a growing patient preference for faster and more accurate diagnostic tests are driving the growth of the hospitals and clinics segment. The majority of the population is dependent on these long-term amenities for diagnostics, medical approaches, and governance. The healthcare industry's constant changes have increased the demand for health facilities that provide advanced diagnostic services. An increase in global health expenditures has contributed significantly to the growth of the hospital and clinics segment.
Lateral Flow Assays Market Regional Overview
The Middle East & Africa (MEA)
North America is expected to lead the global market for lateral flow assays in 2021. Increased communicable disease incidences, combined with increased use of point-of-care testing procedures for secure and early identification, will reinforce regional dominance. High private and government financing organization research and innovation expenditure in the advancement of point of care testing, including lateral flow tests, is expected to accelerate the regional market during the forecast period. Furthermore, the region's prevalence of respiratory infections such as influenza, COVID-19, and RSV is increasing rapidly, necessitating increased monitoring and diagnosis. Furthermore, the presence of a well-established healthcare system and the availability of federal research funding are expected to drive the growth of the market for lateral flow assays in the coming years.
Lateral Flow Assays Market Players
Some of the prominent global lateral flow assays market companies are Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche AG, Merck KGAA, Biomérieux SA, PerkinElmer, Inc., Hologic, Inc., Quidel Corporation, Becton, Dickinson and Company, Bio-rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and Danaher Corporation.
The estimated market size of global lateral flow assays market in 2021 was accounted to be USD 8,256 Million.
The projected CAGR of lateral flow assays during the analysis period of 2022 to 2030 is 5.5%.
The prominent players of the global lateral flow assays market involve Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche AG, Merck KGAA, Biomérieux SA, PerkinElmer, Inc., Hologic, Inc., Quidel Corporation, Becton, Dickinson and Company, Bio-rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and Danaher Corporation.
North America held the dominating share for lateral flow assays during the analysis period of 2022 to 2030
Asia-Pacific region exhibited fastest growing CAGR for lateral flow assays during the analysis period of 2022 to 2030
Rising incidence of infectious disease, growing geriatric population, and growing demand for point-of-care testing are the prominent factors that fuel the growth of global lateral flow assays market
Based on product, kits segment held the maximum share for lateral flow assays market in 2021